Advertisement
Advertisement
U.S. markets open in 7 hours 8 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Invitae Corporation (NVTA)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
2.2900-0.2300 (-9.13%)
At close: 04:00PM EDT
2.3800 +0.09 (+3.93%)
After hours: 07:56PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close2.5200
Open2.5300
Bid0.0000 x 2900
Ask0.0000 x 1800
Day's Range2.2200 - 2.5300
52 Week Range1.8300 - 32.9300
Volume9,136,992
Avg. Volume10,148,877
Market Cap525.072M
Beta (5Y Monthly)1.81
PE Ratio (TTM)N/A
EPS (TTM)-2.0560
Earnings DateNov 07, 2022 - Nov 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.08
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for NVTA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Invitae Corporation
    Analyst Report: Intellia Therapeutics, Inc.Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It’s evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
    Rating
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more
Advertisement
Advertisement